How Many Haemonetics Corporation (NYSE:HAE)’s Analysts Are Bullish?

June 17, 2018 - By Vivian Currie

Haemonetics Corporation (NYSE:HAE) LogoInvestors sentiment increased to 1.18 in 2018 Q1. Its up 0.07, from 1.11 in 2017Q4. It is positive, as 15 investors sold Haemonetics Corporation shares while 81 reduced holdings. 45 funds opened positions while 68 raised stakes. 49.88 million shares or 2.00% less from 50.89 million shares in 2017Q4 were reported.
Cardinal Cap reported 0.18% in Haemonetics Corporation (NYSE:HAE). The Australia-based Macquarie Limited has invested 0.08% in Haemonetics Corporation (NYSE:HAE). Teachers Retirement System Of The State Of Kentucky holds 0.01% or 16,549 shares in its portfolio. Segall Bryant And Hamill Lc holds 0.11% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 66,435 shares. Amer Capital holds 1.01% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 242,400 shares. Point72 Asia (Hong Kong) Ltd has 165 shares. Parametrica Management Ltd owns 5,310 shares or 0.48% of their US portfolio. Boston Advsrs Ltd invested in 0.07% or 39,898 shares. Cornerstone Advsrs Inc, Washington-based fund reported 14 shares. Franklin Resource reported 1.00M shares. Eam Ltd Company has 42,079 shares. Castleark Ltd Liability Corporation, Illinois-based fund reported 234,356 shares. Lazard Asset Management Limited Liability Company accumulated 7,493 shares. Sei Invs Company invested 0% of its portfolio in Haemonetics Corporation (NYSE:HAE). Arizona State Retirement Sys holds 0.06% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 84,275 shares.

Since January 2, 2018, it had 0 insider purchases, and 9 sales for $1.14 million activity. 3,794 shares were sold by Goldstein Dan, worth $360,766. 183 shares were sold by Ryding Neil Mr., worth $16,970 on Thursday, June 7. KROLL MARK W sold $448,434 worth of stock or 7,118 shares. 214 Haemonetics Corporation (NYSE:HAE) shares with value of $19,844 were sold by Scanlan Jacqueline. $39,410 worth of stock was sold by Burke William P. Mr. on Thursday, June 7. Simon – Christopher sold 1,941 shares worth $179,989.

Haemonetics Corporation (NYSE:HAE) Ratings Coverage

Among 3 analysts covering Haemonetics Corp (NYSE:HAE), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Haemonetics Corp had 9 analyst reports since December 21, 2017 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Thursday, June 14. The firm earned “Overweight” rating on Wednesday, May 9 by Morgan Stanley. The rating was maintained by Morgan Stanley on Wednesday, February 7 with “Overweight”. Jefferies maintained the stock with “Buy” rating in Monday, January 8 report. The stock of Haemonetics Corporation (NYSE:HAE) has “Buy” rating given on Wednesday, March 28 by Morgan Stanley. The rating was upgraded by Raymond James to “Market Perform” on Tuesday, January 2. Jefferies maintained Haemonetics Corporation (NYSE:HAE) rating on Thursday, December 21. Jefferies has “Buy” rating and $68.0 target. The rating was upgraded by Morgan Stanley on Tuesday, January 2 to “Overweight”. The stock of Haemonetics Corporation (NYSE:HAE) has “Buy” rating given on Wednesday, February 7 by Jefferies. Below is a list of Haemonetics Corporation (NYSE:HAE) latest ratings and price target changes.

14/06/2018 Broker: Jefferies Old Rating: Buy New Rating: Buy Old Target: $95 New Target: $110 Maintain
09/05/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $77 New Target: $100 Maintain
28/03/2018 Broker: Morgan Stanley Rating: Buy Maintain
07/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $74 New Target: $77 Maintain
07/02/2018 Broker: Jefferies Rating: Buy New Target: $80.0 Maintain
08/01/2018 Broker: Jefferies Rating: Buy New Target: $75.0 Maintain
02/01/2018 Broker: Raymond James Old Rating: Underperform New Rating: Market Perform Upgrade
02/01/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Upgrade
21/12/2017 Broker: Jefferies Rating: Buy New Target: $68.0 Maintain

The stock decreased 4.83% or $4.62 during the last trading session, reaching $91.13. About 8.51 million shares traded or 1294.90% up from the average. Haemonetics Corporation (NYSE:HAE) has risen 121.77% since June 17, 2017 and is uptrending. It has outperformed by 109.20% the S&P500.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $4.76 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It has a 107.21 P/E ratio. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

More news for Haemonetics Corporation (NYSE:HAE) were recently published by: Seekingalpha.com, which released: “S&P indexes swap firms due to shifting market caps; FSB to SmallCap 600” on June 08, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” and published on June 15, 2018 is yet another important article.

Haemonetics Corporation (NYSE:HAE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.